D
Dan Arenson
Researcher at Pfizer
Publications - 4
Citations - 432
Dan Arenson is an academic researcher from Pfizer. The author has contributed to research in topics: Protease & Coronavirus. The author has an hindex of 3, co-authored 4 publications receiving 211 citations.
Papers
More filters
Journal ArticleDOI
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19.
Britton Boras,Rhys M. Jones,Brandon J. Anson,Dan Arenson,Lisa Aschenbrenner,Malina A. Bakowski,Nathan Beutler,Joseph John Binder,Emily I. Chen,Heather Eng,Holly L. Hammond,Jennifer Hammond,Robert Haupt,Robert M. Hoffman,Eugene P. Kadar,Rob Kania,Emi Kimoto,Melanie G. Kirkpatrick,Lorraine F. Lanyon,Emma K. Lendy,Lillis Jonathan Richard,James Logue,Suman Luthra,Chunlong Ma,Stephen W. Mason,Marisa McGrath,Stephen Noell,R. Scott Obach,Matthew N O' Brien,Rebecca E. O’Connor,Kevin Ogilvie,Dafydd R. Owen,Martin Pettersson,Matthew R. Reese,Thomas F. Rogers,Thomas F. Rogers,Romel Rosales,Michelle Rossulek,Jean G. Sathish,Norimitsu Shirai,Claire M. Steppan,Martyn D. Ticehurst,Lawrence W. Updyke,Stuart Weston,Yuao Zhu,Kris M. White,Adolfo García-Sastre,Jun Wang,Arnab K. Chatterjee,Andrew D. Mesecar,Matthew B. Frieman,Annaliesa S. Anderson,Charlotte Moira Norfor Allerton +52 more
TL;DR: In this paper, a phosphate prodrug PF-07304814 was developed to inhibit coronavirus family 3CL protease activity with selectivity over human host protease targets.
Journal ArticleDOI
Hydrolysis in Pharmaceutical Formulations
Kenneth Craig Waterman,Roger C. Adami,Karen M. Alsante,Amy S. Antipas,Dan Arenson,Rebecca Lyn Carrier,Jinyang Hong,Margaret S. Landis,Franco Lombardo,Jaymin C. Shah,Evgenyi Shalaev,Scott Wendell Smith,Hai Wang +12 more
TL;DR: This literature review presents hydrolysis of active pharmaceutical ingredients as well as the effects on dosage form stability due to hydrolyzing of excipients.
Posted ContentDOI
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19
Britton Boras,Rhys M. Jones,Brandon J. Anson,Dan Arenson,Lisa Aschenbrenner,Malina A. Bakowski,Nathan Beutler,Joseph John Binder,Emily I. Chen,Heather Eng,Jennifer Hammond,Robert M. Hoffman,Eugene P. Kadar,Robert Steven Kania,Emi Kimoto,Melanie G. Kirkpatrick,Lorraine F. Lanyon,Emma K. Lendy,Lillis Jonathan Richard,Suman Luthra,Chunlong Ma,Stephen Noell,R. Scott Obach,Kevin Ogilvie,Dafydd R. Owen,Martin Pettersson,Mattew R. Reese,Thomas F. Rogers,Thomas F. Rogers,Michelle Rossulek,Jean G. Sathish,Claire M. Steppan,Martyn D. Ticehurst,Lawrence W. Updyke,Yuao Zhu,Jun Wang,Arnab K. Chatterjee,Andrew D. Mesecar,Annaliesa S. Anderson,Charlotte Moira Norfor Allerton,Matthew B. Frieman,Stuart Weston,Marisa McGrath,James Logue,Robert Haupt,Holly L. Hammond,Stephen W. Mason,Norimitsu Shirai +47 more
TL;DR: The ADME, safety, in vitro, and in vivo antiviral activity data that supports the clinical evaluation of this compound as a potential COVID-19 treatment are presented.
Posted ContentDOI
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19
Britton Boras,Rhys M. Jones,Brandon J. Anson,Dan Arenson,Lisa Aschenbrenner,Malina A. Bakowski,Nathan Beutler,Joseph John Binder,Emily I. Chen,Heather Eng,Holly L. Hammond,Jennifer Hammond,Rob Haupt,Robert M. Hoffman,Eugene P. Kadar,Robert Steven Kania,Emi Kimoto,Melanie G. Kirkpatrick,Lorraine F. Lanyon,Emma K. Lendy,Lillis,James Logue,Suman Luthra,Chuang Ma,Stephen W. Mason,Marisa McGrath,Stephen Noell,Obach Rs,O’Brien Mn,Rebecca E. O’Connor,Kevin Ogilvie,Dafydd R. Owen,Martin Pettersson,Reese Mr,Thomas F. Rogers,Thomas F. Rogers,Michelle Rossulek,Jean G. Sathish,Norimitsu Shirai,Claire M. Steppan,Martyn D. Ticehurst,Lawrence W. Updyke,Stuart Weston,Yuao Zhu,Jun Wang,Abhishek Chatterjee,Andrew D. Mesecar,Matthew B. Frieman,Annaliesa S. Anderson,Charlotte Moira Norfor Allerton +49 more
TL;DR: In this paper, a phosphate prodrug PF-07304814 is metabolized to PF-00835321 which is a potent inhibitor in vitro of the coronavirus family 3CL pro, with selectivity over human host protease targets.